ASX
LCT 0.059   Last updated EOD 19th October 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Home

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

Our lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

 

The Phase I/IIa clinical trial of NTCELL for the treatment of Parkinson’s disease, in New Zealand, met the primary endpoint of safety and in the three-year follow-up showed persistent long-term improvement in some patients. Results from this trial were used to design a larger Phase IIb trial to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. This trial commenced in March 2016. The 26-week results of this trial required further analysis and patients will continue to be monitored in accordance with the study extension protocol.


One year follow-up data in patients from all three groups in May 2018 showed a statistically significant improvement change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state) in the patients who received 40 or 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery. We will continue to monitor patients for longer to examine the clinical significance of this efficacy data.

 

In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand.

— 15 October 2018

Notice of AGM

NOTICE OF ANNUAL GENERAL MEETING DATE OF MEETING Thursday 15 November 2018 TIME OF MEETING 2:00pm (NZT) PLACE OF MEETING Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Read More Read Less

— 15 October 2018

Annual Report 2018

2018 Annual Report

Read More Read Less
Load More

— 16 September 2017

Sir Richard Faull on RNZ National

On Saturday Morning on RNZ National, LCT Scientific Advisor Sir Richard Faull and businessman Bernie Crosby talk to Kim Hill about the work of the University of Auckland Centre for Brain Research and finding a cure for Parkinson's disease.

Read More Read Less

— 13 June 2017

Pig brain cells implanted into brains of people with Parkinson’s

Would you have pig cells implanted in your brain? Some people with Parkinson’s disease have, in the hope it will stop their disease progressing. The approach is still in the early stages of testing, but initial results from four people look promising, with all showing some improvement 18 months after surgery. Living Cell Technologies, based in Auckland, New Zealand, has been developing a treatment that uses cells from the choroid plexus in pigs. This brain structure makes a cocktail of growth factors and signalling molecules known to help keep nerve cells healthy.

Read More Read Less
Load More
icon
— 15 November 2018

LCT Annual General Meeting. To be held at 2pm (NZT) Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Load More
Announcements

— 15 October 2018

Notice of AGM

NOTICE OF ANNUAL GENERAL MEETING DATE OF MEETING Thursday 15 November 2018 TIME OF MEETING 2:00pm (NZT) PLACE OF MEETING Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Read More Read Less

— 15 October 2018

Annual Report 2018

2018 Annual Report

Read More Read Less
Load More
LCT in the News

— 16 September 2017

Sir Richard Faull on RNZ National

On Saturday Morning on RNZ National, LCT Scientific Advisor Sir Richard Faull and businessman Bernie Crosby talk to Kim Hill about the work of the University of Auckland Centre for Brain Research and finding a cure for Parkinson's disease.

Read More Read Less

— 13 June 2017

Pig brain cells implanted into brains of people with Parkinson’s

Would you have pig cells implanted in your brain? Some people with Parkinson’s disease have, in the hope it will stop their disease progressing. The approach is still in the early stages of testing, but initial results from four people look promising, with all showing some improvement 18 months after surgery. Living Cell Technologies, based in Auckland, New Zealand, has been developing a treatment that uses cells from the choroid plexus in pigs. This brain structure makes a cocktail of growth factors and signalling molecules known to help keep nerve cells healthy.

Read More Read Less
Load More
Events
icon
— 15 November 2018

LCT Annual General Meeting. To be held at 2pm (NZT) Pullman Auckland, Regatta Room, Lower Lobby Level, Cnr Princes St & Waterloo Quadrant, Auckland City, New Zealand

Load More
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.